Alston & Bird advised Mustang Bio Inc.
Mustang Bio Inc.,a clinical-stage biopharmaceutical company, has closed a public offering of common stock aimed at raising approximately $40 million.
The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes.
Based in Worcester, MA, and listed on Nasdaq, Mustang focuses on acquiring, developing, and commercializing novel immunotherapies for cancers and rare genetic diseases.
The Alston & Bird team was led by partner Mark McElreath (Picture), senior associate Gerard Hart, and associate Joel Jung (Corporate) and partner Natalie Clayton and associate Ravi Shah (Intellectual Property).
Law Firms: Alston & Bird LLP;
Clients: Mustang Bio;